(69 days)
ELIAS TPO Kit
Not Found
No
The summary describes a standard ELISA kit and an automated processor, neither of which are described as using AI or ML. The performance studies and metrics are typical for an immunoassay.
No
The device is an in vitro diagnostic (IVD) test used to detect and quantify antibodies as an aid in diagnosis, not to treat or prevent a disease.
Yes
The intended use explicitly states, "as an aid in the diagnosis of thyroid autoimmune disease," indicating its purpose is to help identify or confirm a medical condition.
No
The device is an ELISA kit, which is a laboratory test involving physical reagents and processes, not solely software. While it can be used with an automated processor (which likely involves software), the core device itself is a physical kit.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states it's "For the qualitative detection and quantitation of antibodies against the thyroid peroxidase antigen in serum as an aid in the diagnosis of thyroid autoimmune disease." This clearly indicates it's used to examine specimens derived from the human body (serum) to provide information for diagnostic purposes.
- Device Description: The description confirms it's an "enzyme-linked immunosorbent assay (ELISA) for the detection of IgG to thyroid peroxidase in human serum." This further reinforces its use in analyzing human biological samples.
- Performance Studies: The performance studies involve testing human serum samples and evaluating metrics like sensitivity, specificity, and agreement, which are standard for IVD devices.
- Predicate Device: The mention of a "Predicate Device(s)" which is another ELISA kit for TPO antibodies (ELIAS TPO Kit) is a strong indicator that this device is being compared to an existing IVD on the market.
All these points align with the definition of an In Vitro Diagnostic device, which is used to examine specimens derived from the human body to provide information for the diagnosis, prevention, or treatment of a disease or condition.
N/A
Intended Use / Indications for Use
The TPO IgG kit is an Enzyme-Linked Immunosorbent Assay (ELISA) For the qualitative detection and quantitation of antibodies against the thyroid peroxidase antigen in serum as an aid in the diagnosis of thyroid autoimmune disease. The test can be performed either manually or in conjunction with the Mago Plus automated EIA processor.
Product codes (comma separated list FDA assigned to the subject device)
JZO
Device Description
The & TPO IgG ELISA Kit is an enzyme-linked immunosorbent assay (ELISA) for the detection of IgG to thyroid peroxidase in human serum.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
A. Relative Sensitivity and Specificity
Frozen retrospective sera from two hundred fifty-five patients were tested on the Is-anti-TPO IgG TestKit and a commercially available ELISA kit for TPO antibodies. Based on the results of this testing, the relative sensitivity and specificity was calculated.
Relative Sensitivity: 71/71 = 100%
Relative Specificity: 167/172 = 97.1%
Overall Agreement: 238/243 = 97.9%
B. Clinical Sensitivity and Specificity Using Characterized Sera
A total of 207 frozen retrospective, characterized sera were assayed using the Is-anti-TPO IgG Test Kit.
Clinical Specificity (Normals): 160/175 = 91.4%
Clinical Sensitivity (Grave's Disease): 9/14 = 64.3%
Clinical Sensitivity (Hashimoto's Disease): 12/16 = 75.0%
C. Precision
To determine the precision of the Is-anti-TPO IgG Test Kit, four positive sera were assayed ten times each in three different runs at two different sites. The intra- and interassay precision obtained at each site is shown in Tables 4 and 5.
D. Correlation of Manual and MAGO Plus Results
104 serum samples were tested by both manual and MAGO Plus automated procedures. A scattergram and regression line showed a good correlation with a Pearson Correlation Coefficient of 0.977.
E. MAGO Plus Precision
The precision of the Is-anti-TPO IgG Test Kit when performed on the MAGO Plus Automated EIA Processor was determined by assaying six sera ten times each in three different runs. Table 6 shows the intra-and interassay precision obtained using the MAGO Plus.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Relative Sensitivity: 100%
Relative Specificity: 97.1%
Overall Agreement: 97.9%
Clinical Specificity (Normals): 91.4%
Clinical Sensitivity (Grave's Disease): 64.3%
Clinical Sensitivity (Hashimoto's Disease): 75.0%
Pearson Correlation Coefficient: 0.977
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
ELIAS TPO Kit
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 866.5870 Thyroid autoantibody immunological test system.
(a)
Identification. A thyroid autoantibody immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the thyroid autoantibodies (antibodies produced against the body's own tissues). Measurement of thyroid autoantibodies may aid in the diagnosis of certain thyroid disorders, such as Hashimoto's disease (chronic lymphocytic thyroiditis), nontoxic goiter (enlargement of thyroid gland), Grave's disease (enlargement of the thyroid gland with protrusion of the eyeballs), and cancer of the thyroid.(b)
Classification. Class II (performance standards).
0
FEB 2 1999
510k Summary of Safety and Effectiveness
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
1984228 The assigned 510(k) number is:
Applicant Information:
| Date Prepared: | Nov 24, 1998 |
|---|---|
| Name: | Columbia Bioscience, Inc. |
| Address: | 8775 M Centre Park Drive, #559 |
| Columbia, MD 21045 |
| Contact Person: | Norman Jenkins |
|---|---|
| PhoneNumber: | 410-995-0450 |
| Fax Number: | 410-995-0448 |
Device Information:
| Trade Name: | anti-TPO IgG ELISA Kit |
|---|---|
| Common Name: | TPO IgG EIA Test |
| Classification Name: | TPO Serological Reagent |
Equivalent Device: ELIAS TPO Kit
Device Description: The & TPO IgG ELISA Kit is an enzyme-linked immunosorbent assay (ELISA) for the detection of IgG to thyroid peroxidase in human serum.
Intended Use: The TPO IgG kit is an Enzyme-Linked Immunosorbent Assay (ELISA) For the qualitative detection and quantitation of antibodies against the thyroid peroxidase antigen in serum as an aid in the diagnosis of thyroid autoimmune disease. The test can be performed either manually or in conjunction with the Mago Plus automated EIA processor.
Principle of Procedure:
TPO antigen is bound to microwells. Diluted patient sera, Calibrators and controls are placed inthe microwells and incubated. Anti-TPO IgG antibodes, if present, will bind to the antigen-antibody complexes. Residual sample is eliminated by aspirating and washing. Conjugate (horseradish peroxidase-labeled anti-human IgG) is added and will bind to these complexes. Unbound conjugate is removed by aspiration and washing. Substrate is then added and incubated. In the presence of bound enzyme the substrate is converted to an end product. The absorbance of this end product can be read spectrophotometrically at 450 nm (reference 600-630 nm) and is directly proportional to the concentration of IgG antibodies to TPO present in the sample.
1
Performance Characteristics
A. Relative Sensitivity and Specificity
Frozen retrospective sera from two hundred fifty-five patients were tested on the Is-anti-TPO IgG TestKit and a commercially available ELISA kit for TPO antibodies. Based on the results of this testing, the relative sensitivity and specificity was calculated. The results obtained are shown in Table 2:
TABLE 2
Is-anti-TPO IgG
| Other | ||
|---|---|---|
| Ü | ાટે પ |
:
| POSITIVE | * EQUIVOCAL | NEGATIVE | |
|---|---|---|---|
| POSITIVE | 71 | 0 | 0 |
| EQUIVOCAL* | 6 | 0 | 2 |
| NEGATIVE | 5 | 4 | 167 |
| Relative Sensitivity | 71/71 = 100% | 94.9-100 | |
| Relative Specificity | 167/172 = 97.1% | 93.3-99.1 | |
| Overall Agreement | 238/243 = 97.9% | 95.3-99.3 |
- Equivocal results were excluded from calculations
NOTE : Please be advised that 'relative' refers to the comparison of the assay's results to that of a similar assay. There was not an attempt to correlate the assuy's results with disease presence or absence. No judgment can be made on the comparison's accuracy to predict discase.
B. Clinical Sensitivity and Specificity Using Characterized Sera
A total of 207 frozen retrospective, characterized sera were assayed using the Is-anti-TPO IgG Test Kit. The results obtained are shown in Table 3.
| Patient Group: | Positive | Equivocal* | Negative | Total |
|---|---|---|---|---|
| Normals | 15 | 1 | 160 | 176 |
| Grave's Disease | 9 | 1 | 5 | 15 |
| Hashimoto's Disease | 12 | 0 | 4 | 16 |
| Clinical Specificity: | 95% CI | |||
| Normals | = | $160/175 = 91.4%$ | 86.3-95.1 | |
| Clinical Sensitivity: | 95% CI | |||
| Grave's Disease | = | $9/14 = 64.3%$ | 35.1-87.2 | |
| Hashimoto's Disease | = | $12/16 = 75.0%$ | 47.6-92.7 |
TABLE 3
- Equivocal results were excluded from calculations
2
C. Precision
To determine the precision of the Is-anti-TPO IgG Test Kit, four positive sera were assayed ten times each in three different runs at two different sites. The intra- and interassay precision obtained at each site is shown in Tables 4 and 5.
| SERUM | INTRA-ASSAY RUN 1 | INTRA-ASSAY RUN 2 | INTRA-ASSAY RUN 3 | INTERASSAY | ||||
|---|---|---|---|---|---|---|---|---|
| MEAN IU/ml | CV% | MEAN IU/ml | CV% | MEAN IU/ml | CV% | MEAN IU/ml | CV% | |
| A (POS) | 49.2 | 12.19 | 46.8 | 8.76 | 46.6 | 8.80 | 47.5 | 10.10 |
| B (POS) | 99.8 | 14.37 | 91.5 | 7.28 | 91.5 | 7.57 | 94.2 | 11.04 |
| C (POS) | 209.5 | 11.70 | 205.4 | 4.98 | 205.3 | 4.96 | 206.7 | 7.73 |
| D (POS) | 257.5 | 5.16 | 246.5 | 5.97 | 246.2 | 5.93 | 250.1 | 5.89 |
| E (NEG) | 0.6 | 316.23 | 0.2 | 133.13 | 0.1 | 135.53 | 0.1 | 161.76 |
| F (NEG) | 2.4 | 36.15 | 2.6 | 46.33 | 2.6 | 46.08 | 2.5 | 41.92 |
TABLE 4: Site #1-Intra-Assay and Interassay Precision
TABLE 5 : Site #2- Intra-Assay and Interassay Precision
| SERUM | INTRA-ASSAY RUN 1 | INTRA-ASSAY RUN 2 | INTRA-ASSAY RUN 3 | INTERASSAY | ||||
|---|---|---|---|---|---|---|---|---|
| MEAN IU/ml | CV% | MEAN IU/ml | CV% | MEAN IU/ml | CV% | MEAN IU/ml | CV% | |
| A (POS) | 53.5 | 12.64 | 52.3 | 9.65 | 46.0 | 9.93 | 50.6 | 21.47 |
| B (POS) | 105.6 | 19.84 | 93.2 | 9.49 | 87.3 | 6.31 | 95.4 | 15.91 |
| C (POS) | 233.9 | 7.09 | 210.0 | 14.91 | 229.3 | 10.99 | 224.4 | 11.78 |
| D (POS) | 123.1 | 7.10 | 246.6 | 7.51 | 244.2 | 9.30 | 240.6 | 8.29 |
| E (NEG) | 8.8 | 6.35 | 7.8 | 11.40 | 1.5 | 12.17 | 6.0 | 55.73 |
| F (NEG) | 13.1 | 11.21 | 11.7 | 10.67 | 4.0 | 15.90 | 9.6 | 43.97 |
D. Correlation of Manual and MAGO Plus Results
The Is-anti-TPO IgG Test Kit has been developed for automated as well as manual use. To demonstrative equivalence of the manual and MAGO Plus procedures, the results of 104 serum samples tested by both methods were plotted. A scattergram and regression line of the results obtained with 95% confidence intervals is shown in Figure 3. The data indicate good correlation with a Pearson Correlation Coefficient of 0.977.
Image /page/2/Figure/9 description: The image is a title that reads "FIGURE 3 : Correlation of Manual vs MAGO Plus Results". The title is written in a bold, sans-serif font. The words are all capitalized. The title is centered on the image.
Image /page/2/Figure/10 description: This image is a scatter plot comparing MAGO Plus IU/ml to MANUAL IU/ml. The x-axis represents MANUAL IU/ml, ranging from 0 to 1000, while the y-axis represents MAGO Plus IU/ml, ranging from -200 to 1200. The plot shows a positive correlation between the two variables, with data points scattered around a regression line, and the correlation coefficient (r) is 0.977.
3
E. MAGO Plus Precision
The precision of the Is-anti-TPO IgC Test Kit when performed on the MAGO Plus Automated EIA Processor was dctermined by assaying six sera ten times cach in three different runs. Table 6 shows the intra-and interassy precision obtained using the MAGO Plus.
| SERUM | INTRA-ASSAY RUN 1 | INTRA-ASSAY RUN 2 | INTRA-ASSAY RUN 3 | INTERASSAY | ||||
|---|---|---|---|---|---|---|---|---|
| MEAN | ||||||||
| IU/ml | CV% | MEAN | ||||||
| IU/ml | CV% | MEAN | ||||||
| IU/ml | CV% | MEAN | ||||||
| IU/ml | CV% | |||||||
| A (POS) | 76.4 | 14.13 | 71.0 | 11.92 | 75.7 | 13.26 | 74.3 | 13.15 |
| B (POS) | 147.1 | 13.08 | 124.7 | 8.42 | 156.6 | 12.01 | 142.8 | 14.75 |
| C (POS) | 284.6 | 10.39 | 251.8 | 9.95 | 266.7 | 11.35 | 267.7 | 11.43 |
| D (POS) | 321.0 | 16.29 | 320.7 | 17.74 | 351.4 | 20.61 | 331.1 | 16.90 |
| E (NEG) | 1.1 | 36.81 | 2.3 | 16.64 | 1.1 | 49.66 | 1.5 | 48.32 |
| F (NEG) | 7.7 | 33.81 | 6.1 | 20.62 | 6.0 | 19.59 | 6.6 | 29.15 |
TABLE 6 : Site #2- Intra-Assay and Interassay Precision - MAGO Plus
4
Public Health Service
Image /page/4/Picture/2 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features a stylized caduceus symbol, which is a staff with two snakes coiled around it. The symbol is surrounded by the text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" in a circular arrangement. The text is written in a simple, sans-serif font.
EEB 2 1999
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Norman Jenkins COLUMBIA BIOSCIENCE, INC. 8775 M Centre Park Drive, #559 21045 Columbia, MD
K984228 Re: Trade Name: Is-anti-TPO IgG ELISA Test System Requlatory Class: II Product Code: JZO November 24, 1998 Dated: November 25, 1998 Received:
Dear Mr. Jenkins:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in In addition, FDA may publish further regulatory action. announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
5
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"(21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours.
Steven Dutman
Steven I. Gutman, M.D. M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
6
Page 1 of 1
510(k) Number ..
Device Name: 7 TPO IgG ELISA
Indications For Use: The TPO IgG kit is an Enzyme-Linked Immunosorbent Assay (ELISA) for the qualitative detection and quantitation of antibodies against the Thyroid Peroxidase (TPO) antigen in serum as an aid in the diagnosis of thyroid autoimmune disease. The test can be performed either manually or in conjunction with the Mago Plus automated EIA processor.
Peter E. Mapes
| Labels | Values |
|---|---|
| 510(k) Number | K984228 |
PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use V (Per 21 CFR 801.109)
OR
Over-The Counter Use (Optional Format 1-2-96)